Ben Jones on Sequestration and Reimbursement

Video

In Partnership With:

Ben Jones, Senior Director of Government Relations & Public Policy at McKesson Specialty Health & The US Oncology Network, discusses the impact of sequestration on drug and physician reimbursement.

Ben Jones, Senior Director of Government Relations & Public Policy at McKesson Specialty Health & The US Oncology Network, discusses the impact of sequestration on drug and physician reimbursement.

The Community Oncology Alliance has had an ongoing practice and impact study over the last year to gauge the trend of cancer centers closing, consolidating, or affiliating with hospitals. There has been downward pressure as drug reimbursement and physician reimbursement has decreased, Jones says.

Financial issues have only been exacerbated by the implementation of sequestration and its disproportionate application to cancer centers, Jones says, resulting in an accelerated shift in practices closing, consolidating, or affiliating with hospitals. Recently published studies and reports have shown that patients are moving into a more expensive care setting.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD